Treatment options in narcolepsy

Bibliography

• American Academy of Sleep Medicine. The International classification of sleep disorders: diagnostic and coding manual. 2nd edition. American Academy of Sleep Medicine; Westchester, IL: 2005
   Google Scholar
• Hor H, Kutalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010;42:786-9
   PubMed Web of Science ®Google Scholar
• Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep 2007;30:13-26
   PubMed Web of Science ®Google Scholar
• Partinen M, Hublin C. Epidemiology of sleep disorders. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Elsevier Saunders; Philadelphia: 2011. p. 694-715
   Google Scholar
• Poli F, Overeem S, Lammers G, et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 2013;31:994-1007
   PubMedGoogle Scholar
• Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
   PubMed Web of Science ®Google Scholar
• Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-99
   PubMed Web of Science ®Google Scholar
• Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011;43:66-71
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010;33(11):1428-30
   PubMed Web of Science ®Google Scholar
• Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7(3):e33723
   PubMed Web of Science ®Google Scholar
• Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010;120:713-19
   PubMed Web of Science ®Google Scholar
• Fontana A, Gast H, Reith W, et al. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 2010;133(Pt 5):1300-11
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009;73(16):1333-4
   PubMed Web of Science ®Google Scholar
• Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med 2008;4:572-8
   PubMed Web of Science ®Google Scholar
• Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res 2012;1-15
   Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57(11):2029-33
   PubMed Web of Science ®Google Scholar
• Dodel R, Peter H, Spottke A, et al. Health-related quality of life in patients with narcolepsy. Sleep Med 2007;8:733-41
   PubMed Web of Science ®Google Scholar
• Jennum P, Ibsen R, Petersen ER, et al. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med 2012;13:1086-93
   PubMed Web of Science ®Google Scholar
• Rieger M, Mayer G, Gauggel S. Attention deficits in patients with narcolepsy. Sleep 2003;26:31-5
   PubMedGoogle Scholar
• Pizza F, Tartarotti S, Poryazova R, et al. Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: a systematic analysis of 35 consecutive patients. Eur Neurol 2013;70(1-2):22-6
   PubMedGoogle Scholar
• Dauvilliers Y, Paquereau J, Bastuji H, et al. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry 2009;80(6):636-41
   PubMedGoogle Scholar
• Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 2012;7(6):e38977
   PubMed Web of Science ®Google Scholar
• Poli F, Plazzi G, Di Dalmazi G, et al. Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 2010;11(4):423-5
   Google Scholar
• Schuld A, Hebebrand J, Geller F, Pollmächer T. Increased body-mass index in patients with narcolepsy. Lancet 2000;355:1274-5
   PubMed Web of Science ®Google Scholar
• Droogleever Fortuyn HA, Swinkels S, Buitelaar J, et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep 2008;31(3):335-41
   PubMedGoogle Scholar
• American Academy of Sleep Medicine. Practice parameters for the use of stimulants in the treatment of narcolepsy. Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1994;17:348-51
   PubMedGoogle Scholar
• Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13:1035-48
   PubMed Web of Science ®Google Scholar
• Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12):1712-27
   PubMed Web of Science ®Google Scholar
• Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993;16:444-56
   PubMed Web of Science ®Google Scholar
• Helmus T, Rosenthal L, Bishop C, et al. The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals. Sleep 1997;20(4):251-7
   PubMedGoogle Scholar
• Krahn LE, Martin KA, Silber M. Narcoleptic patient's perception of nicotine. J Clin Sleep Med 2009;5:390
   PubMedGoogle Scholar
• Jaehne A, Loessl B, Barkai Z, et al. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep Med Rev 2009;13:363-77
   PubMed Web of Science ®Google Scholar
• Ebben MR, Krieger AC. Narcolepsy with cataplexy masked by the use of nicotine. J Clin Sleep Med 2012;8(2):195-6
   PubMedGoogle Scholar
• Husain AM, Yancy WS Jr, Carwile ST, et al. Diet therapy for narcolepsy. Neurology 2004;62(12):2300-2
   PubMed Web of Science ®Google Scholar
• Schuld A, Blum WF, Uhr M, et al. Reduced leptin levels in human narcolepsy. Neuroendocrinology 2000;72:195-8
   PubMedGoogle Scholar
• Kok SW, Meinders AE, Overeem S, et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 2002;87:805-9
   PubMed Web of Science ®Google Scholar
• Dahmen N, Engel A, Helfrich J, et al. Peripheral leptin levels in narcoleptic patients. Diabetes Tech Ther 2007;9:348-53
   PubMedGoogle Scholar
• Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep 2004;17(8 Suppl):S97-102
   Google Scholar
• Wu H, Xia FZ, Xu H, et al. Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals. Neuropeptides 2012;46(3):113-18
   PubMedGoogle Scholar
• Hill R, Baskwill BE. Positive effect of massage therapy on a patient with narcolepsy. Int J Ther Massage Body Work 2013;6(2):24-8
   PubMedGoogle Scholar
• Dahmen N, Kasten M. REM-associated hallucinations and sleep paralysis are dependent on body posture. J Neurol 2001;248:423-4
   PubMedGoogle Scholar
• Mignot E. A hundred years of narcolepsy research. Arch Ital Biol 2001;139:207-20
   PubMedGoogle Scholar
• Mignot E. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012;9:739-52
   PubMed Web of Science ®Google Scholar
• Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993;16:201-3
   PubMedGoogle Scholar
• Daly DD, Yoss RE. The treatment of narcolepsy with methylphenylpiperidylacetate: a preliminary report. Proc Staff Meet Mayo Clin 1956;31:620-5
   PubMedGoogle Scholar
• Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151-80
   PubMed Web of Science ®Google Scholar
• Mitler MM, Shafor R, Hajdukovik R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986;9:260-4
   PubMed Web of Science ®Google Scholar
• Scammell TE, Saper CB. Orexins: looking forward to sleep, back at addiction. Nat Med 2007;13(2):126-8
   PubMedGoogle Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain. JAMA 2009;301(11):1148-54
   PubMed Web of Science ®Google Scholar
• Palovaara S, Kivisto KT, Tapanainen P, et al. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1-hydroxylation. Brit J Clin Pharmacol 2000;50:333-7
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Rogers AE, Walsleben JA, et al. Health related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-65
   PubMed Web of Science ®Google Scholar
• Ghei M. Case 36-2007: a woman with rash, fever, and hypotension. N Engl J Med 2008;358(13):1405
   PubMedGoogle Scholar
• Sabatine MS, Poh KK, Mega JL, et al. Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med 2007;357(21):2167-78
   PubMedGoogle Scholar
• Bayard S, Langenier MC, Dauvilliers Y. Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy. Sleep 2013;36(9):xxx
   Google Scholar
• Crosby MI, Bradshaw DA, McLay RN. Severe mania complicating treatment of narcolepsy with cataplexy. J Clin Sleep Med 2011;7(2):214-16
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009;29(2):87-100
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA-approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets; 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
   Google Scholar
• Harsh JR, Haydak R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22(4):761-74
   PubMed Web of Science ®Google Scholar
• Black J, Hull SG, Tiller J, et al. Maintenance of efficacy, safety and tolerability of armodafinil: an open-label extension study [Abstract 0419]. Sleep 2009;32(Suppl):A139
   PubMed Web of Science ®Google Scholar
• Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of c-hydroxybutyrate in humans. Behav Pharmacol 2010;21(4):332-42
   PubMedGoogle Scholar
• Mayer G. The use of sodium oxybate to treat narcolepsy. Expert Rev Neurother 2012;12(5):519-29
   PubMed Web of Science ®Google Scholar
• Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009;5(4):365-71
   PubMed Web of Science ®Google Scholar
• Wallace DM, Maze T, Shafazand S. Sodium oxybate induced sleep driving and sleep-related eating disorder. J Clin Sleep Med 2011;7(3):310-11
   PubMedGoogle Scholar
• Seeck-Hirschner M, Baier PC, von Freier A, et al. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports. Sleep Med 2009;10(1):154-5
   PubMedGoogle Scholar
• Poli F, Ricotta L, Vandi S, et al. Catathrenia under sodium oxybate in narcolepsy with cataplexy. Sleep Breath 2012;16(2):427-34
   PubMed Web of Science ®Google Scholar
• Frase L, Schupp J, Sorichter S, et al. Sodium oxybate-induced central sleep apneas. Sleep Med 2013; pii: S1389-9457(13)00207-4; doi:10.1016/j.sleep.2013.03.023
   PubMedGoogle Scholar
• Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 2012;8(4):451-8
   PubMed Web of Science ®Google Scholar
• Boscolo-Berto R, Viel G, Montagnese S, et al. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2012;16(5):431-43
   PubMed Web of Science ®Google Scholar
• Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med 2010;11(5):500-1
   PubMedGoogle Scholar
• US Xyrem multicenter study group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9
   PubMedGoogle Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29(7):939-46
   PubMed Web of Science ®Google Scholar
• Poryazova R, Tartarotti S, Khatami R, et al. Sodium oxybate in narcolepsy with cataplexy: zurich sleep center experience. Eur Neurol 2011;65(3):165-82
   Google Scholar
• Nittur N, Konofal E, Dauvilliers Y, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013;14(1):30-6
   PubMed Web of Science ®Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30(1):74-83
   PubMed Web of Science ®Google Scholar
• Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012;35(2):55-60
   PubMed Web of Science ®Google Scholar
• Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with modafinil. Br J Pharmacol 2013;169(3):632-44
   PubMed Web of Science ®Google Scholar
• U.S. Xyrem® Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23
   PubMedGoogle Scholar
• US Xyrem multicenter study group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-5
   PubMed Web of Science ®Google Scholar
• Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27
   PubMed Web of Science ®Google Scholar
• Sonka K, Kemlink D, Pretl M. Cataplexy treated with escitalopram-clinical experience. Neuroendocrinol Lett 2006;27:174-6
   PubMed Web of Science ®Google Scholar
• Poryazova R, Siccoli M, Werth E, Bassetti C. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005;65:967-8
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Mancuso J, Quera Salva MA, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1994;275-9
   Google Scholar
• Larrosa O, de la Liave Y, Barrio S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy. Sleep 2001;24:282-5
   PubMed Web of Science ®Google Scholar
• Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005;28:1189
   PubMed Web of Science ®Google Scholar
• Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996;5(Suppl 1):217
   Google Scholar
• Izzi F, Placidi F, Marciani MG. Effective treatment of narcolepsy-cataplexy with duloxetine. A report of 3 cases. Sleep Med 2009;10:153-4
   PubMed Web of Science ®Google Scholar
• Mayer G, Meier-Ewert K. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995;18:306-19
   PubMed Web of Science ®Google Scholar
• Mamelak M, Black J, Montplaisir J. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004;27:1327-34
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Snyder M, Aloe FS, et al. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 1992;15:212-16
   PubMed Web of Science ®Google Scholar
• Kansagra S, Walter R, Vaughn B. Nocturnal temazepam in the treatment of narcolepsy. J Clin Sleep Med 2013;9(5):499-500
   PubMedGoogle Scholar
• Pizza F, Moghadam KK, Franceschini C, et al. Rhythmic movements and sleep paralysis in narcolepsy with cataplexy: a video-polygraphic study. Sleep Med 2010;11(4):423-5
   PubMedGoogle Scholar
• Ferri R, Marelli S, Ferini-Strambi L, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med 2013;14:24-9
   PubMedGoogle Scholar
• Dauvilliers Y, Pennestri MH, Petit D, et al. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007;16(3):333-9
   PubMedGoogle Scholar
• Boivin DB, Montplaisir J, Poirier G, The effects of L-Dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989;16:339-45
   Google Scholar
• Boivin DB, Lorrain D, Montplaisir J. Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology 1993;43:2134-6
   PubMed Web of Science ®Google Scholar
• Bedard MA, Montplaisir J, Godbout R, Lapierre O. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989;12:29-36
   PubMed Web of Science ®Google Scholar
• Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med 2007;8(2):181-3
   PubMedGoogle Scholar
• Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 2012;7(6):e38977
   PubMed Web of Science ®Google Scholar
• Maurovich-Horvat E, Kemlink D, Högl B, et al. Narcolepsy and pregnancy: a retrospective evaluation of 249 pregnancies. J Sleep Res 2013; doi: 10.1111/jsr.12047
   PubMedGoogle Scholar
• Thorpy M, Zhao CG, Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med 2013;14(4):367-76
   PubMedGoogle Scholar
• Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-8
   PubMed Web of Science ®Google Scholar
• Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003;26:809-10
   PubMed Web of Science ®Google Scholar
• Coelho FM, Pradella-Hallinan M, Alves GR, et al. Report of two narcoleptic patients with remission of hypersomnolence following use of prednisone. Arq Neuropsiquiatr 2007;65(2A):336-7
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 1994;56:905-8
   Google Scholar
• Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008;255(12):1900-3
   PubMed Web of Science ®Google Scholar
• Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254(11):1607-8
   PubMed Web of Science ®Google Scholar
• Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res 2012;21(4):479-80
   PubMed Web of Science ®Google Scholar
• Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58:489-90
   PubMed Web of Science ®Google Scholar
• Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 2011;12(10):941-6
   PubMed Web of Science ®Google Scholar
• Carlander B, Puech-Cathala AM, Jaussent I, et al. Low vitamin D in narcolepsy with cataplexy. PLoS ONE 2011;6(5):e20433
   Google Scholar
• Arias-Carrión O, Murillo-Rodriguez E, Xu M, et al. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27(8):1465-70
   PubMedGoogle Scholar
• Kantor S, Mochizuki T, Lops SN, et al. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 2013;36(8):1129-38
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Neidhart E, Lecendreux M, et al. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001;6:367-72
   PubMed Web of Science ®Google Scholar
• Donjacour CEHM, Aziz A, Roelfsema F, et al. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab 2011;300:E1069-75
   PubMedGoogle Scholar